Table 2.
Meta-analysis of PRDX-1 and clinicopathological features in solid tumors patients.
| Categories | Trials (patients) | OR (95% CI) | I 2(%) | P h | Z | P |
|---|---|---|---|---|---|---|
| Age (young vs. old) | 15 (2564) | 0.99 (0.73-1.36) | 62.4% | 0.001 | 0.04 | 0.966 |
| Gender (male vs. female) | 13 (1543) | 0.93 (0.74-1.17)F | 21.5% | 0.226 | 0.65 | 0.514 |
| Tumor size (small vs. large) | 12 (1907) | 1.69 (1.07-2.68) | 77.8% | <0.001 | 2.24 | 0.025 |
| TNM stage (I+II vs. III+IV) | 14 (2110) | 2.26 (1.24-4.13) | 87.3% | <0.001 | 2.65 | 0.008 |
| Depth of invasion (T1+T2 vs. T3+T4) | 4 (567) | 1.11 (0.37-3.38) | 87.1% | <0.001 | 0.18 | 0.854 |
| Lymph node metastasis (negative vs. positive) | 10 (1847) | 1.47 (0.93-2.34) | 76.9% | <0.001 | 1.64 | 0.100 |
| Distant metastasis (negative vs. positive) | 2 (174) | 1.94 (0.84-4.47)F | 26.9% | 0.242 | 1.55 | 0.120 |
| Degree of differentiation (poor/not vs. well/moderate) | 7 (808) | 0.59 (0.44-0.81)F | 21.2% | 0.268 | 3.33 | 0.001 |
All pooled ORs were calculated from random-effect model except for cells marked with (fixedF). Ph denotes P value for heterogeneity based on Q test; P denotes P value for statistical significance based on Z test. OR, odds ratio; CI, confidence interval.